GlassScriptPhysician profile
Divyang Trivedi
NPI 1265473730
$3,311.33
in general payments reported to CMS, 2019-2025
17 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $268 · 2021: $230 · 2022: $424 · 2023: $688 · 2024: $1,213 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,033.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,017.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Regeneron Healthcare Solutions, INC. | $514.43 | 2021-2024 | Dupixent |
| Genzyme Corporation | $494.69 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $390.33 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.22 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Optinose US, INC. | $127.65 | 2023-2024 | |
| Csl Behring | $115.32 | 2023-2025 | Haegarda |
| Pfizer INC. | $70.21 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.72 | 2024 | Takhzyro |
| Incyte Corporation | $29.70 | 2023 | Opzelura |
| Pharming Healthcare, INC. | $27.79 | 2021 | |
| Novartis Pharmaceuticals Corporation | $23.50 | 2019 | |
| Hikma Pharmaceuticals USA | $19.86 | 2024 | Ryaltris |
| Amgen INC. | $18.73 | 2023 | Tezspire |
| Genentech USA, INC. | $17.23 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $16.29 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $14.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Divyang Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.